hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06334575, orgStudyIdInfo id: 2023-505245-13-00, briefTitle: Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels, acronym: 3TR-ICS-COPD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Maria Joyera Rodríguez, class: OTHER, descriptionModule briefSummary: The 3TR-ICS COPD study is an international, multicentre, randomized, parallel, controlled study that will recruit clinically stable former smokers COPD patients (with no exacerbations in the previous 8 weeks) on treatment with dual long-acting bronchodilators (LABA+LAMA), minimum 8 weeks of usage, not receiving ICS (either naïve or \> 3 months since last usage). The overall objective of this clinical trial is to identify the molecular signatures associated with the molecular response to ICS treatment in patients with COPD stratified by the levels of circulating eosinophils, and the potential influence of the pulmonary microbiome, conditionsModule conditions: Chronic Obstructive Pulmonary Disease, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 135, type: ESTIMATED, armsInterventionsModule interventions name: Budesonide, outcomesModule primaryOutcomes measure: Significant molecular changes in COPD stratified by their blood eosinophil counts., secondaryOutcomes measure: Significant molecular changes in COPD with different airflow limitation severities., eligibilityModule sex: ALL, minimumAge: 40 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Philips University of Marburg, city: Marburg, country: Germany, contacts name: Peter Alter, role: CONTACT, geoPoint lat: 50.80904, lon: 8.77069, locations facility: Academisch Ziekenhuis Groningen, city: Groningen, country: Netherlands, contacts name: Marteen van den Berge, role: CONTACT, geoPoint lat: 53.21917, lon: 6.56667, locations facility: Clínic Barcelona, city: Barcelona, zip: 08036, country: Spain, contacts name: Alvar Agustí, role: CONTACT, geoPoint lat: 41.38879, lon: 2.15899, locations facility: Son Espases, city: Palma De Mallorca, zip: 07120, country: Spain, contacts name: Francisco de Borja Cosio, role: CONTACT, geoPoint lat: 39.56939, lon: 2.65024, locations facility: University of Leicester, city: Leicester, country: United Kingdom, contacts name: Christopher Brightling, role: CONTACT, geoPoint lat: 52.6386, lon: -1.13169, locations facility: Imperial College London, city: London, country: United Kingdom, contacts name: Lydia J Finney, role: CONTACT, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06334562, orgStudyIdInfo id: KY-2023-112, briefTitle: The Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-01-31, completionDateStruct date: 2025-08-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: The Fourth Affiliated Hospital of Zhejiang University School of Medicine, class: OTHER, descriptionModule briefSummary: This study aims to compare the use of sugammadex (domestic) and neostigmine for antagonism after thoracic surgery, and observe the effect of sugammadex (domestic) on neuromuscular blockade antagonism after thoracic surgery, in order to provide a basis for optimizing the use of muscle relaxants and their antagonists during anesthesia., conditionsModule conditions: Neuromuscular Blockade, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: SUGAMMADEX SODIUM 100 Mg in 1 mL, interventions name: Neostigmine, outcomesModule primaryOutcomes measure: Muscle relaxation recovery time, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06334549, orgStudyIdInfo id: LSKY2023-107-01, briefTitle: A Prospective Study of Vasopressor on Cerebral Oxygenation During General Anesthesia, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-05, primaryCompletionDateStruct date: 2024-12-05, completionDateStruct date: 2024-12-05, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Dalian Municipal Central Hospital, class: OTHER, descriptionModule briefSummary: The purpose of this study is to investigate whether norepinephrine(N), phenylephrine(P) or ephedrine(E) have different effect on cerebral oxygenation in abdominal surgery with propofol or sevoflurane., conditionsModule conditions: Hypotension Drug-Induced, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule interventions name: Ephedrine-P, interventions name: Phenylephrine-P, interventions name: Norepinephrine-P, interventions name: Ephedrine-S, interventions name: Phenylephrine-S, interventions name: Norepinephrine-S, outcomesModule primaryOutcomes measure: Continual changes in Cerebral Oxygen Saturation, secondaryOutcomes measure: Continual changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MAP), secondaryOutcomes measure: Continual changes in heart rate (HR), secondaryOutcomes measure: Continual changes in stroke volume (SV), secondaryOutcomes measure: Continual changes in cardiac output (CO), secondaryOutcomes measure: Continual changes in systemic vascular resistance (SVR), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dalian Municipal Central Hospital, status: RECRUITING, city: Dalian, state: Liaoning, zip: 116033, country: China, contacts name: Liping Han, M.D., role: CONTACT, geoPoint lat: 38.91222, lon: 121.60222, hasResults: False
protocolSection identificationModule nctId: NCT06334536, orgStudyIdInfo id: 0832/66, briefTitle: Multi-country Survey on Violence Against Women Among Medical Staff, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Chulalongkorn University, class: OTHER, collaborators name: Asia and Oceania Federation of Obstetrics and Gynaecology, descriptionModule briefSummary: The goal of this observational study is to investigate the knowledge, attitude, and practice (KAP) towards violence against women (VAW) among medical staff in the Department of Obstetrics and Gynecology in Asia and Oceania countriesThe main question it aims to answer is:* the KAP towards VAW among medical staff in the Department of Obstetrics and Gynecology in Asia and Oceania countries* the KAP towards support service of VAW among medical staff in the Department of Obstetrics and Gynecology in Asia and Oceania countriesParticipants will be asked to complete the online self-administrated questionnaire., conditionsModule conditions: Violence Against Women, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: KAP towards VAW, primaryOutcomes measure: KAP towards support service of VAW, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06334510, orgStudyIdInfo id: HL-SJLG-2021-Ⅳ-01, briefTitle: Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations., statusModule overallStatus: COMPLETED, startDateStruct date: 2021-11-17, primaryCompletionDateStruct date: 2023-01-20, completionDateStruct date: 2023-03-28, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Hualan Biological Bacterin Co. Ltd., class: INDUSTRY, descriptionModule briefSummary: To evaluate the inter-batch consistency (CI) of quadrivalent influenza vaccine (split virion) among healthy people aged 18-59 years； Secondly, to evaluate the safety and immunogenicity of quadrivalent influenza vaccine (split virion) in the expanded population aged 3 years and above, in order to observe the rare adverse reaction of 1‰., conditionsModule conditions: GCP, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 4900, type: ACTUAL, armsInterventionsModule interventions name: One dose of quadrivalent influenza virus split vaccine was administered, outcomesModule primaryOutcomes measure: To evaluate the safety and immunogenicity of Hualan Biovar quadrivalent influenza vaccine in a larger population in the real world, and to observe rare adverse drug reaction (ADR) of 1‰., secondaryOutcomes measure: To explore the consistency of three consecutive batches of commercial vaccines for vaccination in adults aged 18-59 years., eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 74 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kou Zengqiang, city: Jinan, state: Shandong, zip: 250000, country: China, geoPoint lat: 36.66833, lon: 116.99722, hasResults: False
protocolSection identificationModule nctId: NCT06334497, orgStudyIdInfo id: APH220791, secondaryIdInfos id: 2023-506216-40-00, type: OTHER, domain: EU CT, briefTitle: Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections, acronym: LUCY-1, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2027-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Assistance Publique - Hôpitaux de Paris, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate the efficacy and the tolerance of letermovir as part of dual antiviral therapy (in association with valganciclovir) in renal transplant recipients with CMV DNAemia, requiring valganciclovir treatment per investigator's judgment., conditionsModule conditions: Cytomegalovirus Infection, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Letermovir, interventions name: Valganciclovir, interventions name: Letermovir placebo, outcomesModule primaryOutcomes measure: Virological response to treatment on week-3, secondaryOutcomes measure: Eradication of CMV DNAemia (< 200 IU/ml) before Week-12, secondaryOutcomes measure: Number of days between baseline and first measure of CMV DNAemia < 200 IU/mL, secondaryOutcomes measure: Absence of CMV-related symptoms at baseline and each visit, secondaryOutcomes measure: Adverse event (AE) occurence, secondaryOutcomes measure: Sequencing of whole UL97, UL54, UL56, UL89 and UL51 genes, secondaryOutcomes measure: Ganciclovir plasma concentration, secondaryOutcomes measure: Letermovir plasma concentration, secondaryOutcomes measure: Measure of the CMV specific T-cell immunity, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hôpital Necker Enfants Malades, city: Paris, zip: 75015, country: France, contacts name: Laurence BUSSIERES, PhD, role: CONTACT, phone: +33 6 62 08 19 58, email: laurence.bussieres@aphp.fr, geoPoint lat: 48.85341, lon: 2.3488, hasResults: False
protocolSection identificationModule nctId: NCT06334471, orgStudyIdInfo id: INCS_WGS_B-001, briefTitle: Whole Genome Sequencing in Breast Cancer, acronym: WGS SIT, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-08-02, primaryCompletionDateStruct date: 2025-08-02, completionDateStruct date: 2030-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Inocras Korea Inc., class: INDUSTRY, descriptionModule briefSummary: This study aims to conduct whole genome sequencing in breast cancer patients to elucidate individual genetic characteristics and their correlation with breast cancer subtypes. The primary objective is to establish new treatment guidelines aligned with the paradigm shift in precision medicine. The study will include both prospective and retrospective cohorts totaling 1200 participants. Prospective participants must provide consent and be eligible for tissue collection, while retrospective participants must have histologically confirmed breast cancer and available tissue samples from Samsung Medical Center Biobank. The study period spans 3 years for subject enrollment and 5 years for follow-up observations, with an expected completion date of December 31, 2030., conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 1200, type: ESTIMATED, armsInterventionsModule interventions name: no intervention needed, outcomesModule primaryOutcomes measure: Establishing individual genetic characteristics of breast cancer patients through WGS, secondaryOutcomes measure: Analysis of correlation between whole-genome sequencing results and genetic subtypes of breast cancer, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Samsung Medical Center, status: RECRUITING, city: Seoul, country: Korea, Republic of, contacts name: Yeon Hee Park, MD, role: CONTACT, contacts name: Yeon Hee Park, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06334458, orgStudyIdInfo id: IEO 1910, briefTitle: Epigenomic and Machine Learning Models to Predict Pancreatic Cancer, acronym: IMAGene, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-02-03, primaryCompletionDateStruct date: 2024-02-21, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: The goal of the multicentric and interdisciplinary IMAGene project is to pursue early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups, by developing and validating a comprehensive cancer risk prediction algorithm (CRPA) as a clinical support tool to calculate a personalized risk profile.The study is a longitudinal, non-randomized exploratory clinical study. A total of 170 asymptomatic first-degree relatives of PC patients., conditionsModule conditions: Pancreatic Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 170, type: ACTUAL, armsInterventionsModule interventions name: Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups, outcomesModule primaryOutcomes measure: Observation of a two or three-fold enrichment in early detection of suspicious pancreatic lesion using the CRPA algorithm, primaryOutcomes measure: Identification of one or more abnormal methylation changes present in blood cells of participants with suspicious lesions versus methylation profiles of participants with no identified lesions, primaryOutcomes measure: Validation of igenetic biomarker testing in liquid biopsy followed by radiological exam as early cancer diagnostic tool, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Toulouse University Hospital, city: Toulouse, country: France, geoPoint lat: 43.60426, lon: 1.44367, locations facility: European Institute of Oncology, city: Milan, country: Italy, geoPoint lat: 45.46427, lon: 9.18951, locations facility: Oncological Institute "Prof. Dr. Ion Chiricuta", city: Cluj-Napoca, country: Romania, geoPoint lat: 46.76667, lon: 23.6, locations facility: Catalan Institute of Oncology, city: Barcelona, country: Spain, geoPoint lat: 41.38879, lon: 2.15899, hasResults: False
protocolSection identificationModule nctId: NCT06334445, orgStudyIdInfo id: IEO 1874, briefTitle: CARDIOCARE Prospective Clinical Study, acronym: CARDIOCARE, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-14, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: This is a prospective observational study to refine and validate risk stratification algorithms aimed at identifying elderly patients at higher risk of developing cardiotoxicity (us-ing risk factors and potential blood and stool biomarkers) and at assessing whether integrated patient-oriented behavioral and psychological interventions can mitigate, prevent or delay the onset of cardiotoxicity from chemotherapy., conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 736, type: ESTIMATED, armsInterventionsModule interventions name: Control group, interventions name: Intervention group, outcomesModule primaryOutcomes measure: Evaluation of the onset of cardiotoxicity, secondaryOutcomes measure: Intra-patient assessment of major adverse cardiac events (MACEs), secondaryOutcomes measure: Intra-patient assessment of plasma Troponin I, secondaryOutcomes measure: Intra-patient assessment of plasma Brain natriuretic peptide (BNP) elevation, secondaryOutcomes measure: Percentage in the two arm of hospital admission, secondaryOutcomes measure: Number of Cardiovascular death in the two arms, secondaryOutcomes measure: Number of Non-cardiovascular death in the two arms, secondaryOutcomes measure: Evaluation of Health Related Quality of Life in the two arms, secondaryOutcomes measure: Cost-effectiveness of provided healthcare pathways determined by costs combined with quality-adjusted life-years (QALYs) in the two arms, eligibilityModule sex: FEMALE, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Gabriella Pravettoni, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06334406, orgStudyIdInfo id: 098 DRC 210 ER03 012, briefTitle: Antitumor T Cell Responses in Patients With Bladder Cancer, acronym: immunoBLAD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-02, primaryCompletionDateStruct date: 2026-04-02, completionDateStruct date: 2026-04-02, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire de Besancon, class: OTHER, descriptionModule briefSummary: The main objective of this study is to evaluate the induction of Th1 anti-TERT responses by treatments in patients with bladder tumor., conditionsModule conditions: Bladder Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 33, type: ESTIMATED, armsInterventionsModule interventions name: Biological samples, outcomesModule primaryOutcomes measure: Tumor antigen specific T-cell responses, secondaryOutcomes measure: Monitoring of T cells in the blood, secondaryOutcomes measure: Monitoring of immune cell death parameters in the blood, secondaryOutcomes measure: Monitoring of immune suppressive cells in the blood, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Progression-free survival, secondaryOutcomes measure: Local progression-free survival, secondaryOutcomes measure: Transcriptomic analysis, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06334380, orgStudyIdInfo id: 73688, briefTitle: VR for Surgical Prehabilitation and Rehabilitation, acronym: VR-PREP, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, descriptionModule briefSummary: This randomized controlled trial aims to determine feasibility and acceptability of of VR-physical therapy modules for surgical patients undergoing breast or axilla surgery in order to prepare for and recover from surgery., conditionsModule conditions: Breast Cancer, conditions: Frailty, conditions: Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants randomized to one of two arms, VR self-paced modules with live PT guidance and VR without live PT guidance., primaryPurpose: OTHER, maskingInfo masking: SINGLE, maskingDescription: Blinded assessor will conduct adherence calls., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Virtual Reality Modules Only, interventions name: Virtual Reality Modules + Live Physical Therapist Support, outcomesModule primaryOutcomes measure: VR for remote Physical Therapy (PT), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Stanford Hospital and Clinics, city: Palo Alto, state: California, zip: 94305, country: United States, geoPoint lat: 37.44188, lon: -122.14302, hasResults: False